ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Sunday, November 17, 2024

10:30AM-12:30PM: Abstract Number: 1426

Single Cell RNA-Seq Characterization of Circulating Immune Cells in Sjogren’s Syndrome: Comparison to SLE and Rheumatoid Arhtritis

Sjögren's Syndrome – Basic & Clinical Science Poster I

10:30AM-12:30PM: Abstract Number: 0952

Single Cell RNA-seq of Scleroderma-associated Interstitial Lung Disease Lung Explants Reveals an Active, Cytotoxic Natural Killer Cell Population

Systemic Sclerosis & Related Disorders – Basic Science Poster I

10:30AM-12:30PM: Abstract Number: 1425

Sjögren’s Syndrome and Interstitial Lung Disease: Experience in a Collaborative Rheumatology-Pulmonology Clinic

Sjögren's Syndrome – Basic & Clinical Science Poster I

10:30AM-12:30PM: Abstract Number: 1503

Social Connections Among Middle-Aged and Older Adults with Systemic Lupus Erythematosus: A Single Center Cross-Sectional Study

SLE – Diagnosis, Manifestations, & Outcomes Poster II

10:30AM-12:30PM: Abstract Number: 1022

Social Determinants of Health in Osteoporosis Treatment Patterns Among Adults with Rheumatoid Arthritis and Major Osteoporotic Fracture in the All of Us Research Program: A Cross-Sectional Study

Healthcare Disparities in Rheumatology Poster II

10:30AM-12:30PM: Abstract Number: 1418

Soluble Immune Checkpoint Molecules as Biomarkers for Extraglandular Sjögren’s Disease

Sjögren's Syndrome – Basic & Clinical Science Poster I

10:30AM-12:30PM: Abstract Number: 0985

Specific Causes for Hospitalization in Persons with Inflammatory Arthritis Conditions and Gout: A Systematic Review

Epidemiology & Public Health Poster II

10:30AM-12:30PM: Abstract Number: 0986

State-and-County-Level Social Vulnerability Index and Trends in Systemic Lupus Erythematosus-Related Mortality in the U.S

Epidemiology & Public Health Poster II

10:30AM-12:30PM: Abstract Number: 1208

Statin Use and Risk of Total Joint Replacement of Knee and Hip in Osteoarthritis Patients: Study Based on the French National Health Insurance Cohort

Osteoarthritis – Clinical Poster I

10:30AM-12:30PM: Abstract Number: 0963

Stratification According to Autoantibody Status in Systemic Sclerosis Reveals Distinct Molecular Signatures

Systemic Sclerosis & Related Disorders – Basic Science Poster I

10:30AM-12:30PM: Abstract Number: 1155

Stratification of Cancer Risk in Idiopathic Inflammatory Myopathies. Application of the IMACS Guidelines to Enhance Screening

Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster II

10:30AM-12:30PM: Abstract Number: 1629

Subclinical Giant Cell Arteritis in Polymyalgia Rheumatica Has a Different Vascular Ultrasound Phenotype Than Giant Cell Arteritis

Vasculitis – Non-ANCA-Associated & Related Disorders Poster II

10:30AM-12:30PM: Abstract Number: 1216

Subcutaneous Methylnaltrexone Treatment of Opioid-Induced Constipation in Adults with Rheumatic Conditions

Pain in Rheumatic Disease Including Fibromyalgia Poster

10:30AM-12:30PM: Abstract Number: 1177

Supporting Implementation of Group Physical Therapy for Knee Osteoarthritis: Results of a Multisite Implementation Trial

Orthopedics, Low Back Pain, & Rehabilitation – ACR/ARP Poster

10:30AM-12:30PM: Abstract Number: 1412

Survival and Predictive Markers of Prognosis in Patients with Cancer Occurrence After Sjögren Syndrome: A Long-term Observational Study

Sjögren's Syndrome – Basic & Clinical Science Poster I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].